Litcius/Paper detail

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design

Francesco Passiglia, Paolo Bironzo, Luisella Righi, Angela Listì, Francesca Arizio, Silvia Novello, Marco Volante, Giorgio V. Scagliotti

2020Clinical Lung Cancer31 citationsDOIOpen Access PDF

Topics & Concepts

MedicineLung cancerMesotheliomaCancer researchOncologyCancerInternal medicinePARP inhibitorImmunotherapyPoly ADP ribose polymerasePathologyDNAPolymeraseBiologyGeneticsPARP inhibition in cancer therapyAdvancements in Semiconductor Devices and Circuit DesignDNA Repair Mechanisms
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design | Litcius